肝がん治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、地域別、セグメント予測、2023年～2030年

肝がん治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、肝がん治療薬の世界市場規模は2030年までに78億3,000万米ドルに達し、予測期間中のCAGRは15.3％を記録すると予測されています。

肝がん市場の成長は、新薬の入手可能性、強力なパイプラインの存在、社会的認知度の上昇といった要因によって大きく左右されます。肝臓がん患者の裾野の広がりは、不健康な生活習慣や老年人口の増加に起因しています。これは肝がん治療薬市場に有利に働いています。ネクサバールに不耐容の患者を対象としたセカンドライン治療薬の開発は、肝がん領域に大きな影響を与えると推定されます。

肝がんは世界で5番目に罹患率の高いがんであり、がんによる死亡者数の9.0%を占めています。2012年には782,451人が新たに肝がんと診断され、745,533人が肝がんで死亡したと報告されています。原発性肝がんは、その極めて侵攻的な性質と生存率の低さから、依然として重要な公衆衛生上の問題です。肝細胞がんは原発性肝がんの大部分（75～90％）を占める。肝炎感染や肝硬変を含む肝がんの注目すべき多くの病因因子は修正可能であり、生活習慣の改善や肝炎の予防接種などの予防戦略によって、その発生率や死亡率を低下させる強い見通しを示しています。

肝がん治療薬市場レポートハイライト

• 北米は2022年に市場の43.20%以上を占める。複数の製品上市、新規治療薬の採用増加、対象人口の多さが同地域の市場成長に寄与しています。
• 近年、複数の新薬が承認されたことは、肝がん治療市場を拡大する重要な要因の一つです。免疫腫瘍学の新製品と併用療法は、今後数年間で状況を一変させると予想されます。
• 特にチェックポイント阻害剤を含む併用療法は、腫瘍抵抗性の克服、無増悪生存期間の改善、QOLの維持など、主要なアンメットニーズをターゲットに、ファーストライン治療に導入されるでしょう。
• 肝がん市場のパイプラインは非常に革新的で多様性に富んでいます。アンメットニーズが高いため、画期的なファースト・イン・クラスの治療薬を開発する絶好の機会となっています。近年では、オンコリティックウイルスやRNA干渉（RNAi）技術などの革新的な治療アプローチが市場で大きな支持を得ています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 肝がん治療薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 普及と成長の見通しマッピング
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 肝がん治療薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 肝がん治療薬市場：薬剤クラスの推定・動向分析

• 肝がん治療薬市場：重要なポイント
• 肝がん治療薬市場：薬剤クラスの動向と市場シェア分析、2022年および2030年
• 標的療法
• 免疫療法
• 化学療法

第5章 肝がん治療薬市場：地域の推定・動向分析

• 地域別の展望
• 地域別の肝がん治療薬市場：重要なポイント
• 北米
  • 市場推計・予測、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第6章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 市場参入企業の分類
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Merck KGaA

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 3 North America liver cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 4 U.S. liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 5 Canada liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 6 Europe liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 7 Europe liver cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 8 Germany liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 9 UK liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 10 France liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 11 Italy liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 12 Spain liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 13 Denmark liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 14 Sweden liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 15 Norway liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 16 Asia Pacific liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 17 Asia Pacific liver cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 18 China liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 19 Japan liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 20 India liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 21 Australia liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 22 Thailand liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 23 South Korea liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 24 Latin America liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 25 Latin America liver cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 26 Brazil liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 27 Mexico liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 28 Argentina liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 29 Middle East and Africa liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 30 Middle East and Africa liver cancer drugs market, by region, 2018 - 2030 (USD Million)
• Table 31 South Africa liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 32 Saudi Arabia liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 33 UAE liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 34 Kuwait liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 QFD modeling for market share assessment
• Fig. 6 Market formulation & validation
• Fig. 7 Liver cancer drugs: Market outlook
• Fig. 8 Liver cancer drugs: Competitive insights
• Fig. 9 Parent market outlook
• Fig. 10 Related/ancillary market outlook
• Fig. 11 Penetration and growth prospect mapping
• Fig. 12 Liver cancer drugs market driver impact
• Fig. 13 Liver cancer drugs market restraint impact
• Fig. 14 Liver cancer drugs market strategic initiatives analysis
• Fig. 15 Liver cancer drugs market: Drug class movement analysis
• Fig. 16 Liver cancer drugs market: Drug class outlook and key takeaways
• Fig. 17 Targeted therapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Immunotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Chemotherapy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Global liver cancer drugs market: Regional movement analysis
• Fig. 21 Global liver cancer drugs market: Regional outlook and key takeaways
• Fig. 22 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Liver Cancer Drug Market Growth & Trends:

The global liver cancer drug market size is expected to reach USD 7.83 billion by 2030, registering a CAGR of 15.3% during the forecast period, according to a new report by Grand View Research, Inc.. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75-90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

Liver Cancer Drug Market Report Highlights:

• The North America accounted for more than 43.20% of the market in 2022. Multiple product launches, increasing adoption of novel therapeutics, and presence of a large target population are contributing to the growth of the market in the region
• Approval of multiple novel drugs in recent years is one of the key factors augmenting the liver cancer treatment market. New immuno-oncology products and combination therapies are anticipated to change the landscape over the next years.
• Combination regimens, specifically those including checkpoint inhibitors, will be introduced in the first-line setting to target major unmet needs, including overcoming tumour resistance, improving progression free survival, and maintaining quality of life
• The liver cancer market pipeline is highly innovative and diverse. The market offers tremendous opportunities to develop breakthrough first-in-class therapies due to high unmet needs. In recent years, innovative treatment approaches such as oncolytic viruses or RNA interference (RNAi) technology have gained significant traction in the market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Drug Class
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Liver Cancer Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Liver Cancer Drugs Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's Five Forces
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Liver Cancer Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Liver Cancer Drugs Market: Key Takeaways
• 4.2. Liver Cancer Drugs Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
• 4.3. Targeted Therapy
  • 4.3.1. Targeted therapy market estimates and forecasts, 2018 to 2030, (USD Million)
• 4.4. Immunotherapy
  • 4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030, (USD Million)
• 4.5. Chemotherapy
  • 4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030, (USD Million)

Chapter 5. Liver Cancer Drugs Market: Regional Estimates & Trend Analysis

• 5.1. Regional Outlook
• 5.2. Liver Cancer Drugs Market by Region: Key Takeaways
• 5.3. North America
  • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.4. Europe
  • 5.4.1. UK
    • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.2. Germany
    • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.3. France
    • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.4. Italy
    • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.5. Spain
    • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.6. Denmark
    • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4.8. Norway
    • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Japan
    • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.2. China
    • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.3. India
    • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.4. Australia
    • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.5. Thailand
    • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5.6. South Korea
    • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.6. Latin America
  • 5.6.1. Brazil
    • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6.2. Mexico
    • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6.3. Argentina
    • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 5.7. MEA
  • 5.7.1. South Africa
    • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7.4. Kuwait
    • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Market Participant Categorization
  • 6.2.1. Bayer AG
    • 6.2.1.1. Company overview
    • 6.2.1.2. Financial performance
    • 6.2.1.3. Product benchmarking
    • 6.2.1.4. Strategic initiatives
  • 6.2.2. Bristol-Myers Squibb Company
    • 6.2.2.1. Company overview
    • 6.2.2.2. Financial performance
    • 6.2.2.3. Product benchmarking
    • 6.2.2.4. Strategic initiatives
  • 6.2.3. Eisai Co., Ltd.
    • 6.2.3.1. Company overview
    • 6.2.3.2. Financial performance
    • 6.2.3.3. Product benchmarking
    • 6.2.3.4. Strategic initiatives
  • 6.2.4. Exelixis, Inc.
    • 6.2.4.1. Company overview
    • 6.2.4.2. Financial performance
    • 6.2.4.3. Product benchmarking
    • 6.2.4.4. Strategic initiatives
  • 6.2.5. Merck KGaA
    • 6.2.5.1. Company overview
    • 6.2.5.2. Financial performance
    • 6.2.5.3. Product benchmarking
    • 6.2.5.4. Strategic initiatives